Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | APC inact mut |
Gene Variant Detail | |
Relevant Treatment Approaches | CTNNB1 Inhibitor Tankyrase Inhibitor |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05761951 | Phase II | DKN-01 + Pembrolizumab | Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer | Recruiting | USA | 0 |
NCT04851119 | Phase Ib/II | BC2059 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | Recruiting | USA | 0 |
NCT02675946 | Phase I | CGX1321 CGX1321 + Pembrolizumab Cetuximab + CGX1321 + Encorafenib | CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) | Unknown status | USA | 1 |
NCT05919264 | Phase Ib/II | FOG-001 | FOG-001 in Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |